Cite
MLA Citation
Mikhail N Kosiborod et al.. “Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial.” Lancet, vol. 9, no. 9, 2021, pp. 586–594. http://access.bl.uk/ark:/81055/vdc_100144511921.0x000005